Inventor · disambiguated record
Jan Elsner
Also filed as: ELSNER JAN
22 granted patents·3 pending applications·274 citations·filing 2009–2023
96Inventor score
Files withSIGNAL PHARM LLC14PERRIN-NINKOVIC SOPHIE3SIGNAL PHARMACEUTICAL LLC3BAHMANYAR SOGOLE2BENNETT BRYDON L1
Top patents by PatentIndex Score
25 records- 0196US9701643B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Jul 11, 2017·19 cites·18 claims
- 0296US8492381B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Jul 23, 2013·44 cites·21 claims
- 0396US8110578B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2009·Granted Feb 7, 2012·67 cites·28 claims
- 0494US10040770B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2017·Granted Aug 7, 2018·7 cites·18 claims
- 0594US9139534B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithBENNETT BRYDON L·Filed 2012·Granted Sep 22, 2015·30 cites·76 claims
- 0693US10266500B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2018·Granted Apr 23, 2019·5 cites·14 claims
- 0793US8507492B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Aug 13, 2013·22 cites·20 claims
- 0892US11325890B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2020·Granted May 10, 2022·2 cites·18 claims
- 0991US8569494B2Methods of synthesis and purification of heteroaryl compoundsHARRIS ROY L·Filed 2010·Granted Oct 29, 2013·27 cites·23 claims
- 1088US9771371B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2015·Granted Sep 26, 2017·4 cites·6 claims
- 1187US8299056B2Aminotriazolopyridines, compositions thereof, and methods of treatment therewithBAHMANYAR SOGOLE·Filed 2009·Granted Oct 30, 2012·22 cites·31 claims
- 1286US10919865B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2019·Granted Feb 16, 2021·3 cites·16 claims
- 1384US9079900B2Methods of synthesis and purification of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2014·Granted Jul 14, 2015·5 cites·27 claims
- 1484US8907087B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Granted Dec 9, 2014·4 cites·11 claims
- 1583US9428509B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2014·Granted Aug 30, 2016·6 cites·32 claims
- 1683US9346812B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2014·Granted May 24, 2016·6 cites·30 claims
- 1780US12129237B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2022·Granted Oct 29, 2024·0 cites·6 claims
- 1880US10167290B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2017·Granted Jan 1, 2019·1 cites·5 claims
- 1980US2023119470A1PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAYSIGNAL PHARM LLC·Filed 2022·Application pending·0 cites
- 2074US11292796B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2020·Granted Apr 5, 2022·0 cites·5 claims
- 2172US10683298B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2018·Granted Jun 16, 2020·0 cites·8 claims
- 2270US9193692B2Halogen substituted pyrazines as intermediates of mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2014·Granted Nov 24, 2015·0 cites·14 claims
- 2357US2024158370A1CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDSINNOVO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2453US9795607B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2016·Granted Oct 24, 2017·0 cites·33 claims
- 2543US2013005707A1Aminotriazolopyridines, compositions thereof, and methods of treatment therewithBAHMANYAR SOGOLE·Filed 2012·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →